Search
Back 

Time to Biochemical Failure Could be Used as a Surrogate Endpoint in Treatment of Locally Advanced Prostate Cancer

Time to Biochemical Failure Could be Used as a Surrogate Endpoint in Treatment of Locally Advanced Prostate Cancer

For Immediate Release
Media Contact: 

Angela LaPenta
lapentaa@nrgoncology.org

James Dignam, PhD

PHILADELPHIA, PA– An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure (IBF), or the time it takes for previously treated cancer to return as indicated by prostate specific antigen (PSA) rise, could be used as a surrogate endpoint for locally advanced prostate cancer. Previously, surrogate endpoints based on PSA, which are alternate endpoints that could determine the effectiveness of a treatment earlier than traditional clinical endpoints, have been tested and evaluated with radiotherapy and short-term androgen deprivation. However, surrogate endpoints for long-term androgen deprivation, a proven therapy in high-risk, localized cancers, have not been investigated. The results of this analysis are published in the Journal of Clinical Oncology.

“The main goal of this trial study was to determine if time interval free of biochemical failure could stand as a surrogate endpoint for the effect of long-term androgen deprivation on two clinical endpoints: prostate cancer-specific survival and overall survival,” stated James Dignam, PhD, of the Department of Public Health Sciences at University of Chicago and the NRG Oncology Statistics and Data Management Center, a member of the Cancer Prevention and Control research program at the University of Chicago Medicine Comprehensive Cancer Center, and the lead author of the NRG-RTOG 9202 analysis.

NRG-RTOG 9202 randomly assigned 1,520 men to one of two treatment arms. Treatment Arm 1 received short-term androgen deprivation (AD) therapy for four months; whereas Treatment Arm 2 received long-term AD for approximately 28 months. Survival modeling and landmark analysis methods were applied to evaluate the associations between long-term AD, IBF, prostate-specific survival, and overall survival.

“Men who remained free of biochemical failure for three years had significantly more favorable overall survival and prostate cancer-specific survival,” added Dr. Dignam. “Additionally, data showed that 50% of the men who experienced biochemical failure by three years died of prostate cancer as of 15 years, as opposed to 19% among the men who were still free of biochemical failure at three years.”

Accounting for three-year IBF status reduced the long-term AD overall survival benefit from 12% (hazard ratio (HR, 0.88; 95% CI, 0.79 to 0.98) to 6% (HR, 0.94; 95% CI, 0.83 to 1.07). For prostate cancer-specific survival, long-term AD benefit was reduced from 30% (HR, 0.70; 95% CI, 0.52 to 0.82) to 6% (HR, 0.94; 95% CI, 0.72 to 1.22). These findings satisfied the surrogacy criteria, as IBF identified the benefit for long-term AD on disease-specific and overall survival, suggesting that IBF has the potential to serve as a valid primary endpoint if validated in a proper meta-analysis. Even if not used as a primary endpoint, IBF is an informative intermediate endpoint in Phase II/III clinical trials, and may aid in patient risk monitoring after initial treatment.

This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), and UG1CA189867 (NCORP) from the U.S. National Cancer Institute (NCI), National Institutes of Health. We gratefully acknowledge the contribution of the late Gerald E. Hanks, MD, to this manuscript.

Citation

Dignam JJ, Hamstra DA, Lepor H, Grignon D, Brereton H, Currey A, Rosenthal S, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Sandler HM. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2018 Dec 7:JCO1800154. doi: 10.1200/JCO.18.00154. [Epub ahead of print] PubMed PMID: 30526194.

About NRG Oncology 
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.

 

 

Copyright 2019 by NRG Oncology